- Home
- LGND vs AB Comparison
LGND vs AB Comparison
Compare LGND & AB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LGND | AB |
|---|---|---|
| Founded | 1987 | 1987 |
| Country | United States | United States |
| Employees | 68 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 3.7B |
| IPO Year | N/A | 1994 |
Fundamental Metrics
Financial Performance| Metric | LGND | AB |
|---|---|---|
| Price | $210.74 | $38.50 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 7 | 5 |
| Target Price | ★ $256.29 | $40.40 |
| AVG Volume (30 Days) | 162.9K | ★ 273.7K |
| Earning Date | 05-07-2026 | 04-28-2026 |
| Dividend Yield | N/A | ★ 8.59% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $1.25 | N/A |
| Revenue Next Year | $19.41 | $6.45 |
| P/E Ratio | $76.27 | ★ $13.85 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $98.90 | $35.59 |
| 52 Week High | $247.38 | $44.11 |
Technical Indicators
Market Signals| Indicator | LGND | AB |
|---|---|---|
| Relative Strength Index (RSI) | 42.39 | 46.78 |
| Support Level | $198.23 | $37.67 |
| Resistance Level | $232.12 | $39.62 |
| Average True Range (ATR) | 9.52 | 0.72 |
| MACD | -2.47 | -0.17 |
| Stochastic Oscillator | 30.90 | 18.60 |
Price Performance
Historical ComparisonAbout LGND Ligand Pharmaceuticals Incorporated
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.
About AB AllianceBernstein Holding L.P.
AllianceBernstein provides investment management services to institutional (41% of assets under management), retail (41%), and private (18%) clients through products that includes mutual funds, hedge funds, and separately managed accounts. At the end of February 2026, the company had $880.0 billion in managed assets, composed primarily of fixed-income (37% of AUM) and equity (40%) strategies, with other investments (made up of asset allocation services and certain other alternative investments) accounting for the remainder.